“Expanded Access” and “Compassionate Use” are terms that are utilized in our rare disease community, but what do they mean? How do patients learn about, get involved, better understand the qualifications, and talk with their doctor about participation in either of these programs? Join MitoAction and Dr. Koenig as we dive deep into better understanding the differences and overlap between “Expanded Access” and “Compassionate Use” therapies.
Genetic Testing – Genome Sequencing: A-Z for Mitochondrial Disease
The underlying cause of LCHADD retinopathy is not fully understood. This presentation will look at the research that identifies the cell in the eye...
MitoAction welcomes Dr. David Holtzman to discuss “dysautonomia”. Dysautonomia is a failure of the autonomic nervous system to regulate certain body functions, such as...
